Roche Gets an FDA Approval for a Rare Kidney Disease

Most investors will not have heard of primary membranous nephropathy. That is precisely the point. While the name rarely surfaces in earnings calls or financial headlines, Roche announced on November 16, 2026 that the FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria. It is a quiet approval with a loud implication: a drug already on the market is extending its commercial life into territory no competitor has claimed.

Primary membranous nephropathy is a rare chronic autoimmune disease that, in the absence of treatment, can progress to kidney failure in roughly one-third of patients within 10 years. Until this FDA decision, clinicians had no FDA-approved therapy to offer those patients. This is the first drug approved specifically for the treatment of adults with primary membranous nephropathy, and Gazyva was previously approved for treating certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome. The same molecule, the same manufacturing infrastructure, a new commercial runway.

The Trial Numbers That Matter

The MAJESTY Phase III study was designed to evaluate the efficacy and safety of obinutuzumab in adults with primary membranous nephropathy, enrolling 142 adults randomized 1:1 to receive Gazyva or tacrolimus. The gap in outcomes was not marginal. At week 104, about 37% of patients receiving Gazyva achieved complete remission of proteinuria versus 6% with tacrolimus. Against a standard immunosuppressant that physicians have used for decades, Gazyva delivered six times the complete remission rate. Regulators noticed: Gazyva received Breakthrough Therapy, Orphan Drug, and Priority Review designations for this approval.

The Bigger Franchise at Work

What wealth-focused investors should appreciate is the compounding logic of indication expansion. This is the third FDA approval of Gazyva in immune-mediated kidney disease, following approvals in lupus nephritis and childhood-onset idiopathic nephrotic syndrome. Each new approval adds patients, refills the sales trajectory, and justifies continued investment in the molecule.

The commercial momentum was already building before today. In 2025, Gazyva sales grew 14% to CHF 986 million from CHF 910 million in 2024. Roche management has set a more ambitious benchmark: the company remains confident that Gazyva could add 2 billion Swiss francs in peak annual sales across immunology indications. Today’s approval moves that target closer.

What This Means for RHHBY Holders

Roche trades on the U.S. OTC market as RHHBY, and the investment case here is not about a dramatic re-rating. It is about durability. Roche has increased its dividend for 39 consecutive years. Roche has paid dividends since 1993. Those distributions do not come from excitement; they come from a pipeline that reliably converts research into approved products that generate recurring revenue.

Roche delivered 6% sales growth at constant exchange rates in the first half of 2026, driven by high demand for innovative medicines and diagnostics, and the company expects to further increase its dividend in Swiss francs. Indication expansion in an uncontested disease category is exactly the kind of catalyst that sustains that guidance.

Risks to Monitor

Primary membranous nephropathy is rare. The estimated incidence in adults is about 1.2 per 100,000 people in the United States per year, which caps the near-term revenue ceiling for this specific indication. Currency remains a persistent headwind: the Swiss franc’s strength has already pressured Roche’s reported numbers, and that dynamic has not fully resolved. Investors buying RHHBY are also accepting the risk that biosimilar competition in older oncology indications eventually compresses margins in the segments funding today’s immunology build-out.

The Wealth Builder Takeaway

The lesson here runs deeper than a single kidney disease approval. When a large pharmaceutical company owns a proven molecule with a well-understood safety record and a mechanism that addresses multiple diseases, it can generate new approvals at a fraction of the cost required to bring a brand-new drug to market. Gazyva is now approved in six distinct indications across oncology and immune-mediated diseases. Each one extends earnings visibility and supports the dividend that long-term investors depend on. That is not speculation. It is the quiet compounding that builds durable wealth.

More From Author

Tokenized Stocks Go 24/7 on November 23. Your Weekend Positions Just Changed.

SpaceX Caught a Starship From Orbit. Amazon Lost 40 Satellites.

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Categories